Skip to content
Peptigraph home

DREAM: Dapiglutide Phase 2 trial (NCT05788601)

Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial

Registry record checked

At a glance

Phase
Phase 2
Status
Active, not recruiting
Enrolment
54
estimated
Start
27 Apr 2023 (actual)
Primary completion
24 Apr 2024 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen
Design

Arms and doses

NCT05788601 study arms
ArmTypeInterventionsDescription
Placebo (4 mg and 6 mg)Placebo comparatorDrug: PlaceboAbdominal s.c. self-administration of placebo content once weekly for 12 weeks. To ensure double-blinding, the placebo arm is divided into a 4-mg and 6-mg arm. But both placebo arms are pooled during data analysis.
4 mg dapiglutideActive comparatorDrug: DapiglutideAbdominal s.c. self-administration of 4 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks until the remaining nine weeks of treatment (12 weeks in total)
6 mg dapiglutideActive comparatorDrug: DapiglutideAbdominal s.c. self-administration of 6 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks to 4 mg and again to 6 mg after six weeks until the remaining six weeks of treatment (12 weeks in total)
Endpoints

Primary endpoint

NCT05788601 primary outcomes
MeasureTime frame
Percentage change in body weight (kg)From week 0 (baseline) to week 12 (end of treatment)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05788601 secondary outcomes
MeasureTime frame
Body weight reduction ≥ 5%From week 0 (baseline) to week 12 (end of treatment)
Body weight reduction ≥ 10%From week 0 (baseline) to week 12 (end of treatment)
Change in fasting serum/plasma concentrations of gut permeability biomarker (LPS-binding protein (LBP))From week 0 (baseline) to week 12 (end of treatment)
Change in fasting serum/plasma concentrations of inflammation markers (hs-CRP and IL-6)From week 0 (baseline) to week 12 (end of treatment)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated TrialClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.